Clinical Trial Update: Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study comparing EC145 alone, EC145 plus docetaxel, and docetaxel alone for second-line non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• EC145 (vintafolide)

Snippet

Sponsor: Endocyte | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED